Top

Current Treatment Options in Neurology

Published in:

10-06-2023 | Polyneuropathy

Article Topic: Neuropathies Due to Infections and Antimicrobial Treatments

Authors: Andrés M. De León, MD, Rocio Garcia-Santibanez, MD, Taylor B. Harrison, MD

Published in: Current Treatment Options in Neurology | Issue 7/2023

Abstract

Purpose of eview

The aim of this review is to discuss the presentation, diagnosis, and management of polyneuropathy (PN) in selected infections. Overall, most infection related PNs are an indirect consequence of immune activation rather than a direct result of peripheral nerve infection, Schwann cell infection, or toxin production, though note this review will describe infections that cause PN through all these mechanisms. Rather than dividing them by each infectious agent separately, we have grouped the infectious neuropathies according to their presenting phenotype, to serve as a guide to clinicians. Finally, toxic neuropathies related to antimicrobials are briefly summarized.

Recent findings

While PN from many infections is decreasing, increasing evidence links infections to variants of GBS. Incidence of neuropathies secondary to use of HIV therapy has decreased over the last few years.

Summary

In this manuscript, a general overview of the more common infectious causes of PN will be discussed, dividing them across clinical phenotypes: large- and small-fiber polyneuropathy, Guillain-Barré syndrome (GBS), mononeuritis multiplex, and autonomic neuropathy. Rare but important infectious causes are also discussed.

Schifitto G, McDermott MP, McArthur JC, Marder K, Sacktor N, Epstein L, et al. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology. 2002;58(12):1764–8.CrossRefPubMed

So YT, Holtzman DM, Abrams DI, Olney RK. Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey. Arch Neurol. 1988;45(9):945–8.

Morgello S, Estanislao L, Simpson D, Geraci A, DiRocco A, Gerits P, et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch Neurol. 2004;61(4):546–51.CrossRefPubMed

Schifitto G, McDermott MP, McArthur JC, Marder K, Sacktor N, McClernon DR, et al. Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology. 2005;64(5):842–8.CrossRefPubMed

Evans SR, Ellis RJ, Chen H, Yeh TM, Lee AJ, Schifitto G, et al. Peripheral neuropathy in HIV: prevalence and risk factors. AIDS. 2011;25(7):919–28. https://doi.org/10.1097/QAD.0b013e328345889d.CrossRefPubMed

Pandya R, Krentz HB, Gill MJ, Power C. HIV-related neurological syndromes reduce health-related quality of life. Can J Neurol Sci. 2005;32(2):201–4.CrossRefPubMed

Pettersen JA, Jones G, Worthington C, Krentz HB, Keppler OT, Hoke A, et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol. 2006;59(5):816–24.CrossRefPubMed

RJ Ellis D Rosario DB Clifford JC McArthur D Simpson T Alexander et al 2010 Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study Arch Neurol. 2010;67(5):552-558. https://doi.org/10.1001/archneurol.2010.76.

Cornblath DR, McArthur JC. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology. 1988;38(5):794–6.CrossRefPubMed

10.

Berger AR, Arezzo JC, Schaumburg HH, Skowron G, Merigan T, Bozzette S, et al. 2’,3’-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology. 1993;43(2):358–62.CrossRefPubMed

11.

Lewis W, Kohler JJ, Hosseini SH, Haase CP, Copeland WC, Bienstock RJ, et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS. 2006;20(5):675–84. https://doi.org/10.1097/01.aids.0000216367.23325.58.CrossRefPubMed

12.

Martin C, Solders G, Sonnerborg A, Hansson P. Antiretroviral therapy may improve sensory function in HIV-infected patients: a pilot study. Neurology. 2000;54(11):2120–7.CrossRefPubMed

13.

Markus R, Brew BJ. HIV-1 peripheral neuropathy and combination antiretroviral therapy. Lancet. 1998;352(9144):1906–7.CrossRefPubMed

14.

Vecchio AC, Marra CM, Schouten J, Jiang H, Kumwenda J, Supparatpinyo K, et al. Distal sensory peripheral neuropathy in human immunodeficiency virus type 1-positive individuals before and after antiretroviral therapy initiation in diverse resource-limited settings. Clin Infect Dis. 2020;71(1):158–65. https://doi.org/10.1093/cid/ciz745.CrossRefPubMed

15.

Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–73. https://doi.org/10.1016/S1474-4422(14)70251-0.CrossRefPubMedPubMedCentral

16.

Moulignier A, Authier FJ, Baudrimont M, Pialoux G, Belec L, Polivka M, et al. Peripheral neuropathy in human immunodeficiency virus-infected patients with the diffuse infiltrative lymphocytosis syndrome. Ann Neurol. 1997;41(4):438–45.CrossRefPubMed

17.

Gherardi RK, Chretien F, Delfau-Larue MH, Authier FJ, Moulignier A, Roulland-Dussoix D, et al. Neuropathy in diffuse infiltrative lymphocytosis syndrome: an HIV neuropathy, not a lymphoma. Neurology. 1998;50(4):1041–4.CrossRefPubMed

18.

WHO. Hepatitis B.https://www.whoint/news-room/fact-sheets/detail/hepatitis-b. Accessed 3/21/23.

19.

Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine. 2005;84(5):313–22. https://doi.org/10.1097/01.md.0000180792.80212.5e.CrossRefPubMed

20.

Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010;62(2):616–26. https://doi.org/10.1002/art.27240.CrossRefPubMed

21.

Criado PR, Marques GF, Morita TC, de Carvalho JF. Epidemiological, clinical and laboratory profiles of cutaneous polyarteritis nodosa patients: Report of 22 cases and literature review. Autoimmun Rev. 2016;15(6):558–63. https://doi.org/10.1016/j.autrev.2016.02.010.CrossRefPubMed

22.

•• Hocevar A, Tomsic M, Perdan Pirkmajer K. Clinical approach to diagnosis and therapy of polyarteritis nodosa. Curr Rheumatol Rep. 2021;23(3):14. https://doi.org/10.1007/s11926-021-00983-2. High yield review on current management recommendations for patients with PAN.

23.

Guillevin L, Lhote F, Leon A, Fauvelle F, Vivitski L, Trepo C. Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol. 1993;20(2):289–98.

24.

Guillevin L, Mahr A, Cohen P, Larroche C, Queyrel V, Loustaud-Ratti V, et al. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum. 2004;51(3):482–7. https://doi.org/10.1002/art.20401.CrossRefPubMed

25.

WHO. Hepatitis C.https://www.whoint/news-room/fact-sheets/detail/hepatitis-c. accessed 03/21/2023.

26.

Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine. 2000;79(1):47–56.

27.

Santoro L, Manganelli F, Briani C, Giannini F, Benedetti L, Vitelli E, et al. Prevalence and characteristics of peripheral neuropathy in hepatitis C virus population. J Neurol Neurosurg Psychiatry. 2006;77(5):626–9. https://doi.org/10.1136/jnnp.2005.081570.CrossRefPubMedPubMedCentral

28.

Yoon MS, Obermann M, Dockweiler C, Assert R, Canbay A, Haag S, et al. Sensory neuropathy in patients with cryoglobulin negative hepatitis-C infection. J Neurol. 2011;258(1):80–8. https://doi.org/10.1007/s00415-010-5686-1.CrossRefPubMed

29.

Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. Lancet. 2012;379(9813):348–60. https://doi.org/10.1016/S0140-6736(11)60242-0.CrossRefPubMed

30.

Parlati L, Hollande C, Pol S. Treatment of hepatitis C virus infection. Clin Res Hepatol Gastroenterol. 2021;45(4):101578. https://doi.org/10.1016/j.clinre.2020.11.008.

31.

•• Quartuccio L, Bortoluzzi A, Scire CA, Marangoni A, Del Frate G, Treppo E et al. Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC). Clin Rheumatol. 2023;42(2):359–70. https://doi.org/10.1007/s10067-022-06391-w. This manuscript presents good review of the role of rituxmab which is increasingly utilized to treat sequelae of HCV-associated cryoglobulinemia.

32.

WHO. Leprosy.https://www.whoint/news-room/fact-sheets/detail/leprosy. 2023;accessed 3/30/23.

33.

Sharma R, Singh P, McCoy RC, Lenz SM, Donovan K, Ochoa MT et al. Isolation of Mycobacterium lepromatosis and development of molecular diagnostic assays to distinguish Mycobacterium leprae and M. lepromatosis. Clin Infect Dis. 2020;71(8):e262-e9. https://doi.org/10.1093/cid/ciz1121.

34.

Haroun OMO, Vollert J, Lockwood DN, Bennett DLH, Pai VV, Shetty V et al. Clinical characteristics of neuropathic pain in leprosy and associated somatosensory profiles: a deep phenotyping study in India. Pain Rep. 2019;4(6):e743. https://doi.org/10.1097/PR9.0000000000000743.

35.

Croft RP, Nicholls PG, Richardus JH, Smith WC. Incidence rates of acute nerve function impairment in leprosy: a prospective cohort analysis after 24 months (The Bangladesh Acute Nerve Damage Study). Lepr Rev. 2000;71(1):18–33. https://doi.org/10.5935/0305-7518.20000004.CrossRefPubMed

36.

Britton WJ. The management of leprosy reversal reactions. Lepr Rev. 1998;69(3):225–34.PubMed

37.

van Veen NH, Nicholls PG, Smith WC, Richardus JH. Corticosteroids for treating nerve damage in leprosy. A Cochrane review Leprosy review. 2008;79(4):361–71.CrossRefPubMed

38.

• Ebenezer GJ, Scollard DM. Treatment and evaluation advances in leprosy neuropathy. Neurotherapeutics. 2021;18(4):2337–50. https://doi.org/10.1007/s13311-021-01153-z. A good review of current management practicies in Hansen’s disease with discussion of future directions.

39.

Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barre syndrome. Lancet. 2016;388(10045):717–27. https://doi.org/10.1016/S0140-6736(16)00339-1.CrossRefPubMed

40.

Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barre syndrome. J Infect Dis. 1997;176(Suppl 2):S92–8.CrossRefPubMed

41.

Leonhard SE, van der Eijk AA, Andersen H, Antonini G, Arends S, Attarian S, et al. An International perspective on preceding infections in Guillain-Barre syndrome: the IGOS-1000 cohort. Neurology. 2022;99(12):e1299–313. https://doi.org/10.1212/WNL.0000000000200885.CrossRefPubMed

42.

Chiesa M, Decima R, Bertinat A, Poggi L, Hackembruch H, Montenegro C et al. Incidence of Guillain-Barre syndrome in an Uruguayan population. A prospective cohort study. J Peripher Nerv Syst. 2021;26(2):209–15. https://doi.org/10.1111/jns.12450.

43.

Kasemsap N, Vorasoot N, Kongbunkiat K, Tiamkao S, Chotmongkol V, Sawanyawisuth K, et al. The epidemiology of Guillain-Barre syndrome in Thailand over 13 years (2005–2017): a nationwide population-based retrospective cohort study. J Peripher Nerv Syst. 2021;26(2):202–8. https://doi.org/10.1111/jns.12453.CrossRefPubMed

44.

Nachamkin I, Arzarte Barbosa P, Ung H, Lobato C, Gonzalez Rivera A, Rodriguez P, et al. Patterns of Guillain-Barre syndrome in children: results from a Mexican population. Neurology. 2007;69(17):1665–71. https://doi.org/10.1212/01.wnl.0000265396.87983.bd.CrossRefPubMed

45.

Jacobs BC, Rothbarth PH, van der Meche FG, Herbrink P, Schmitz PI, de Klerk MA, et al. The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study. Neurology. 1998;51(4):1110–5.CrossRefPubMed

46.

Dutta D, Debnath M, Nagappa M, Das SK, Wahatule R, Sinha S, et al. Antecedent infections in Guillain-Barre syndrome patients from south India. J Peripher Nerv Syst. 2021;26(3):298–306. https://doi.org/10.1111/jns.12459.CrossRefPubMed

47.

Leonhard SE, Mandarakas MR, de Assis Aquino Gondim F, Bateman K, Brito Ferreira ML, Cornblath DR et al. [Evidence based guidelines. Diagnosis and management of Guillain-Barre syndrome in ten steps]. Medicina (B Aires). 2021;81(5):817–36.

48.

Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barre syndrome. N Engl J Med. 1995;333(21):1374–9. https://doi.org/10.1056/NEJM199511233332102.CrossRefPubMed

49.

Liu F, Lee SA, Xue J, Riordan SM, Zhang L. Global epidemiology of campylobacteriosis and the impact of COVID-19. Front Cell Infect Microbiol. 2022;12:979055. https://doi.org/10.3389/fcimb.2022.979055.

50.

Van Koningsveld R, Van Doorn PA, Schmitz PI, Ang CW, Van der Meche FG. Mild forms of Guillain-Barre syndrome in an epidemiologic survey in The Netherlands. Neurology. 2000;54(3):620–5.CrossRefPubMed

51.

Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet. 2005;366(9497):1653–66. https://doi.org/10.1016/S0140-6736(05)67665-9.CrossRefPubMed

52.

Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci U S A. 2004;101(31):11404–9. https://doi.org/10.1073/pnas.0402391101.CrossRefPubMedPubMedCentral

53.

Wijdicks EF, Klein CJ. Guillain-Barre Syndrome. Mayo Clin Proc. 2017;92(3):467–79. https://doi.org/10.1016/j.mayocp.2016.12.002.CrossRefPubMed

54.

Uncini A, Kuwabara S. Nodopathies of the peripheral nerve: an emerging concept. J Neurol Neurosurg Psychiatry. 2015;86(11):1186–95. https://doi.org/10.1136/jnnp-2014-310097.CrossRefPubMed

55.

Ostman C, Chacko B. Guillain-Barre syndrome post renal transplant: A systematic review. Transpl Infect Dis. 2019;21(1):e13021. https://doi.org/10.1111/tid.13021.

56.

Cronin S, McNicholas R, Kavanagh E, Reid V, O’Rourke K. Anti-glycolipid GM2-positive Guillain-Barre syndrome due to hepatitis E infection. Ir J Med Sci. 2011;180(1):255–7. https://doi.org/10.1007/s11845-010-0635-7.CrossRefPubMed

57.

Maurissen I, Jeurissen A, Strauven T, Sprengers D, De Schepper B. First case of anti-ganglioside GM1-positive Guillain-Barre syndrome due to hepatitis E virus infection. Infection. 2012;40(3):323–6. https://doi.org/10.1007/s15010-011-0185-6.CrossRefPubMed

58.

Van Koningsveld R, Schmitz PI, Ang CW, Groen J, Osterhaus AD, Van der Meche FG, et al. Infections and course of disease in mild forms of Guillain-Barre syndrome. Neurology. 2002;58(4):610–4.CrossRefPubMed

59.

van den Berg B, van der Eijk AA, Pas SD, Hunter JG, Madden RG, Tio-Gillen AP, et al. Guillain-Barre syndrome associated with preceding hepatitis E virus infection. Neurology. 2014;82(6):491–7. https://doi.org/10.1212/WNL.0000000000000111.CrossRefPubMed

60.

Kuwahara M, Samukawa M, Ikeda T, Morikawa M, Ueno R, Hamada Y, et al. Characterization of the neurological diseases associated with Mycoplasma pneumoniae infection and anti-glycolipid antibodies. J Neurol. 2017;264(3):467–75. https://doi.org/10.1007/s00415-016-8371-1.CrossRefPubMed

61.

Parra B, Lizarazo J, Jimenez-Arango JA, Zea-Vera AF, Gonzalez-Manrique G, Vargas J, et al. Guillain-Barre syndrome associated with Zika virus infection in Colombia. N Engl J Med. 2016;375(16):1513–23. https://doi.org/10.1056/NEJMoa1605564.CrossRefPubMed

62.

Styczynski AR, Malta J, Krow-Lucal ER, Percio J, Nobrega ME, Vargas A et al. Increased rates of Guillain-Barre syndrome associated with Zika virus outbreak in the Salvador metropolitan area, Brazil. PLoS Negl Trop Dis. 2017;11(8):e0005869. https://doi.org/10.1371/journal.pntd.0005869.

63.

Leonhard SE, Tan CY, van der Eijk AA, Reisin RR, Franken SC, Huizinga R, et al. Antecedent infections in Guillain-Barre syndrome in endemic areas of arbovirus transmission: a multinational case-control study. J Peripher Nerv Syst. 2021;26(4):449–60. https://doi.org/10.1111/jns.12469.CrossRefPubMedPubMedCentral

64.

•• Keddie S, Pakpoor J, Mousele C, Pipis M, Machado PM, Foster M et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome. Brain. 2021;144(2):682–93. https://doi.org/10.1093/brain/awaa433. Large cohort study that evaluated the relationship between GBS and COVID infection which finds no association between COVID and GBS.

65.

Umapathi T, Er B, Koh JS, Goh YH, Chua L. Guillain-Barre syndrome decreases in Singapore during the COVID-19 pandemic. J Peripher Nerv Syst. 2021;26(2):235–6. https://doi.org/10.1111/jns.12439.CrossRefPubMedPubMedCentral

66.

Harrison TB, Smith B. Neuromuscular manifestations of HIV/AIDS. J Clin Neuromuscul Dis. 2011;13(2):68–84. https://doi.org/10.1097/CND.0b013e318221256f.CrossRefPubMed

67.

Wang Y, Yang J, Wen Y. The peculiarity of infection and immunity correlated with Guillain-Barre syndrome in the HIV-infected population. J Clin Med. 2023;12(3). https://doi.org/10.3390/jcm12030907.

68.

Sharma NC, Efstratiou A, Mokrousov I, Mutreja A, Das B, Ramamurthy T. Diphtheria Nat Rev Dis Primers. 2019;5(1):81. https://doi.org/10.1038/s41572-019-0131-y.CrossRefPubMed

69.

Piradov MA, Pirogov VN, Popova LM, Avdunina IA. Diphtheritic polyneuropathy: clinical analysis of severe forms. Arch Neurol. 2001;58(9):1438–42. https://doi.org/10.1001/archneur.58.9.1438.CrossRefPubMed

70.

Logina I, Donaghy M. Diphtheritic polyneuropathy: a clinical study and comparison with Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 1999;67(4):433–8. https://doi.org/10.1136/jnnp.67.4.433.CrossRefPubMedPubMedCentral

71.

Creange A, Meyrignac C, Roualdes B, Degos JD, Gherardi RK. Diphtheritic neuropathy. Muscle Nerve. 1995;18(12):1460–3. https://doi.org/10.1002/mus.880181217.CrossRefPubMed

72.

Kaur D, Tiwana H, Stino A, Sandroni P. Autonomic neuropathies. Muscle Nerve. 2021;63(1):10–21. https://doi.org/10.1002/mus.27048.CrossRefPubMed

73.

Freeman R, Roberts MS, Friedman LS, Broadbridge C. Autonomic function and human immunodeficiency virus infection. Neurology. 1990;40(4):575–80.CrossRefPubMed

74.

Gluck T, Degenhardt E, Scholmerich J, Lang B, Grossmann J, Straub RH. Autonomic neuropathy in patients with HIV: course, impact of disease stage, and medication. Clin Auton Res. 2000;10(1):17–22.CrossRefPubMed

75.

Compostella C, Compostella L, D’Elia R. The symptoms of autonomic dysfunction in HIV-positive Africans. Clin Auton Res. 2008;18(1):6–12. https://doi.org/10.1007/s10286-007-0451-y.CrossRefPubMed

76.

Robinson-Papp J, Sharma SK. Autonomic neuropathy in HIV is unrecognized and associated with medical morbidity. AIDS Patient Care STDS. 2013;27(10):539–43. https://doi.org/10.1089/apc.2013.0188.CrossRefPubMedPubMedCentral

77.

Chimelli L, Martins AR. Degenerative and inflammatory lesions in sympathetic ganglia: further morphological evidence for an autonomic neuropathy in AIDS. J NeuroAIDS. 2002;2(3):67–82.PubMed

78.

Polydefkis M, Yiannoutsos CT, Cohen BA, Hollander H, Schifitto G, Clifford DB, et al. Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy. Neurology. 2002;58(1):115–9. https://doi.org/10.1212/wnl.58.1.115.CrossRefPubMed

79.

Freeman R, Abuzinadah AR, Gibbons C, Jones P, Miglis MG, Sinn DI. Orthostatic hypotension: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72(11):1294–309. https://doi.org/10.1016/j.jacc.2018.05.079.CrossRefPubMed

80.

Carod-Artal FJ. Infectious diseases causing autonomic dysfunction. Clin Auton Res. 2018;28(1):67–81. https://doi.org/10.1007/s10286-017-0452-4.CrossRefPubMed

81.

Perez-Molina JA, Molina I. Chagas disease. Lancet. 2018;391(10115):82–94. https://doi.org/10.1016/S0140-6736(17)31612-4.CrossRefPubMed

82.

•• Crespillo-Andujar C, Comeche B, Hamer DH, Arevalo-Rodriguez I, Alvarez-Diaz N, Zamora J et al. Use of benznidazole to treat chronic Chagas disease: an updated systematic review with a meta-analysis. PLoS Negl Trop Dis. 2022;16(5):e0010386. https://doi.org/10.1371/journal.pntd.0010386. This adds to the evidence that treatment of chronic Chagas disease shows limited benefit in the adult population.

83.

Perez-Molina JA, Perez-Ayala A, Moreno S, Fernandez-Gonzalez MC, Zamora J, Lopez-Velez R. Use of benznidazole to treat chronic Chagas’ disease: a systematic review with a meta-analysis. J Antimicrob Chemother. 2009;64(6):1139–47. https://doi.org/10.1093/jac/dkp357.CrossRefPubMed

84.

Morales D, Pacurariu A, Slattery J, Pinheiro L, McGettigan P, Kurz X. Association between peripheral neuropathy and exposure to oral fluoroquinolone or Amoxicillin-Clavulanate therapy. JAMA Neurol. 2019;76(7):827–33. https://doi.org/10.1001/jamaneurol.2019.0887.CrossRefPubMedPubMedCentral

85.

Tan IL, Polydefkis MJ, Ebenezer GJ, Hauer P, McArthur JC. Peripheral nerve toxic effects of nitrofurantoin. Arch Neurol. 2012;69(2):265–8. https://doi.org/10.1001/archneurol.2011.1120.CrossRefPubMed

Title: Article Topic: Neuropathies Due to Infections and Antimicrobial Treatments
Authors: Andrés M. De León, MD
Rocio Garcia-Santibanez, MD
Taylor B. Harrison, MD
Publication date: 10-06-2023
Publisher: Springer US
Keywords: Polyneuropathy
Guillain-Barré Syndrome
Human Immunodeficiency Virus
Published in: Current Treatment Options in Neurology / Issue 7/2023
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI: https://doi.org/10.1007/s11940-023-00756-5

At a glance: The STEP trials

Springer Medicine

Article Topic: Neuropathies Due to Infections and Antimicrobial Treatments

Abstract

Purpose of eview

Recent findings

Summary

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of eview

Recent findings

Summary

Please log in to get access to this content